title: Apolipoprotein E in Guamanian amyotrophic lateral sclerosis/parkinsonism-dementia complex: genotype analysis and relationships to neuropathological changes.
abstract: Apolipoprotein E (Apo E) has been recently identified within amyloid deposits and neurofibrillary tangles in the brains of Alzheimer's disease (AD) patients. A strong association of the Apo E epsilon 4 allele with higher risk of developing AD has also been reported. In the present study, the distribution of Apo E and the possible relationship between Apo E alleles and neuropathological alterations were analyzed in a series of Guamanian amyotrophic lateral sclerosis/parkinsonism-dementia complex (ALS/PDC) cases, a neurodegenerative condition characterized neuropathologically by widespread, severe neurofibrillary tangle formation but rare amyloid deposits. ApoE immunoreactivity was consistently observed in both type of lesions in these cases. Compared to tau protein immunoreactivity, there were generally fewer Apo E-immunoreactive neurofibrillary tangles, particularly in the deep layers of the neocortex and in the hippocampus. Genotype analysis revealed that the epsilon 4 allele frequency was 5.9%, the epsilon 3 allele frequency 88.2%, and the epsilon 2 allele frequency 5.9% in this series. Recent data suggest that the Apo E4 variant may induce amyloidogenesis, while E2 could have a neuroprotective role. However, the rare Guamanian patients with amyloid deposits in cortical areas were not related to the epsilon 4 allele, since all cases with senile plaques were epsilon 3/epsilon 3. In addition, compared to unaffected Guamanian cases and other Asian-Pacific populations previously reported, the observed low frequency of the epsilon 2 allele in the present cases, which may be consistent with the notion that this allele, may represent a neuroprotective factor in several neurodegenerative disorders. The present data indicate that there is a strong interaction between Apo E deposition and neurofibrillary changes in Guamanian ALS-PDC.
authors.affiliation: INSERM U422, Lille, France.
authors.forename: L
authors.initials: L
authors.lastname: Buée
authors.forename: J
authors.initials: J
authors.lastname: Pérez-Tur
authors.forename: B
authors.initials: B
authors.lastname: Leveugle
authors.forename: V
authors.initials: V
authors.lastname: Buée-Scherrer
authors.forename: E J
authors.initials: EJ
authors.lastname: Mufson
authors.forename: A J
authors.initials: AJ
authors.lastname: Loerzel
authors.forename: M C
authors.initials: MC
authors.lastname: Chartier-Harlin
authors.forename: D P
authors.initials: DP
authors.lastname: Perl
authors.forename: A
authors.initials: A
authors.lastname: Delacourte
authors.forename: P R
authors.initials: PR
authors.lastname: Hof
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000690:Amyotrophic Lateral Sclerosis / Q000235:genetics* / Q000473:pathology*; D001057:Apolipoproteins E / Q000032:analysis / Q000235:genetics*; D003704:Dementia / Q000235:genetics* / Q000473:pathology*; D005838:Genotype; D006141:Guam; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D016874:Neurofibrillary Tangles / Q000473:pathology; D010300:Parkinson Disease / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D016875:tau Proteins / Q000032:analysis
chemical_list: D001057:Apolipoproteins E; D016875:tau Proteins